GNS561, A NEW ORAL CLINICAL-STAGE SMALL MOLECULE COMBINED WITH ANTI-PD1 SHOWED REMARKABLE ANTI-TUMOR EFFECTS IN A TRANSGENIC IMMUNOCOMPETENT HEPATOCELLULAR CARCINOMA MOUSE MODEL (ASV-B)
https://hal-amu.archives-ouvertes.fr/hal-02466433 Contributor : Isabelle CombeConnect in order to contact the contributor Submitted on : Tuesday, February 4, 2020 - 2:30:18 PM Last modification on : Tuesday, January 25, 2022 - 4:28:02 PM
Rachid, Madani, Tijeras-Raballand, Annemilai, Cindy Serdjebi, Sonia Brun, Christelle Ansaldi, et al.. GNS561, A NEW ORAL CLINICAL-STAGE SMALL MOLECULE COMBINED WITH ANTI-PD1 SHOWED REMARKABLE ANTI-TUMOR EFFECTS IN A TRANSGENIC IMMUNOCOMPETENT HEPATOCELLULAR CARCINOMA MOUSE MODEL (ASV-B). Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Nov 2019, Boston, MA, United States. pp.1189A. ⟨hal-02466433⟩